Related Experiment Video

Updated: Jul 15, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials

Sean I Savitz1, Marc Fisher

  • 1Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA. ssavitz@bidma.harvard.edu

Annals of Neurology
|April 11, 2007
PubMed

Insights

Neuroprotective therapy for acute ischemic stroke faces challenges due to preclinical-to-clinical translation gaps. New strategies are needed to improve the assessment of novel neuroprotective drugs for better patient outcomes.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Neurology

Background:

  • Neuroprotective therapy aims to protect brain tissue and improve outcomes in acute ischemic stroke.
  • Extensive preclinical studies show efficacy, yet most neuroprotective drugs fail in clinical trials.
  • The Stroke Therapy Academic Industry Roundtable (STAIR) provides guidelines for rational preclinical and clinical studies.

Purpose of the Study:

  • To discuss the challenges in translating preclinical findings of neuroprotective drugs to clinical efficacy in acute ischemic stroke.
  • To explore reasons for the failure of neuroprotective drugs in clinical trials, including SAINT-I and SAINT-II.
  • To propose new suggestions for bridging the gap between animal models and human stroke trials for future drug assessment.

Main Methods:

  • Review of preclinical and clinical trial methodologies for neuroprotective agents.
  • Analysis of the Stroke-Acute-Ischaemic-NXY-Treatment (SAINT-I and SAINT-II) trials.
  • Discussion of STAIR guidelines and their impact on drug development.

Main Results:

  • Despite promising preclinical data and adherence to STAIR guidelines in SAINT-I, the SAINT-II trial failed to replicate positive outcomes for NXY-059.
  • The failure of NXY-059 in SAINT-II has raised concerns about the future of neuroprotection for acute ischemic stroke.
  • Inconsistencies highlight potential flaws in preclinical testing and clinical development programs.

Conclusions:

  • Bridging the chasm between preclinical animal modeling and acute human stroke trials is crucial for advancing neuroprotection.
  • New suggestions are needed to enhance the future assessment of novel neuroprotective drugs.
  • Improving the translation of preclinical efficacy to clinical benefit remains a significant challenge in stroke therapy.

More Related Videos

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique07:34

Induction of Acute Ischemic Stroke in Mice Using the Distal Middle Artery Occlusion Technique

Published on: December 15, 2023

Related Concept Videos

Ischemic Stroke ll: Pathophysiology01:15

Ischemic Stroke ll: Pathophysiology

An ischemic stroke occurs when a cerebral blood vessel becomes obstructed, most often by a thrombus or embolus, interrupting the delivery of oxygen and glucose to brain tissue. Because neurons rely on continuous aerobic metabolism, energy failure begins within minutes of reduced perfusion. The region receiving the least blood flow becomes the infarct core, an area of irreversible cellular death. Surrounding this core lies the penumbra, a zone of hypoperfused but still viable tissue that is...
Ischemic Stroke l: Introduction01:15

Ischemic Stroke l: Introduction

Ischemic stroke is an acute cerebrovascular condition in which blood flow to a brain region is suddenly interrupted, leading to tissue infarction. Neurons depend on continuous oxygen and glucose supply, so even brief reductions in perfusion cause energy failure, ionic imbalance, and irreversible injury. Ischemic strokes are classified into thrombotic and embolic types based on their underlying mechanisms.Thrombotic MechanismsThrombotic stroke develops when a clot forms within a cerebral artery.